Technical Analysis of Cytokinetics, Incorporated (NASDAQ:CYTK)


Technical Indicators and Signals

The stochastic oscillator indicator is the important indicator to compare the security price over a certain period of time. The stochastic %K of Cytokinetics, Incorporated (NASDAQ:CYTK) for the period of 9-Day stands at 14.52% while the stochastic %D for the same period stands at 15.14%.

The 7-Day Average Directional Index ADX (also known as Trend Strength Indicator) of Cytokinetics, Incorporated (NASDAQ:CYTK) signals “Sell” while other important signals like the 20-Day Moving Average Vs. Price signals “Sell”.

Another important signal of trend and momentum of a security is 20-50 Day MACD Oscillator or Moving Average Convergence Divergence signals “Sell” for Cytokinetics, Incorporated (NASDAQ:CYTK) while 20-100 Day MACD Oscillator indicates “Sell”.

Bollinger band is a volatility indicator of a certain security, currently Cytokinetics, Incorporated (NASDAQ:CYTK)’s 20-Day Bollinger Band indicates “Hold”.

About Company

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtivmecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with AstellasPharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.

Previous Day Activity Analysis

On the last trading day, Cytokinetics, Incorporated (NASDAQ:CYTK) opened the session at $12.5 and after going down -7.57% closed at $11.6. The stock lost -0.9 points in the last trade.

Cytokinetics, Incorporated (NASDAQ:CYTK)’s stock fluctuated in the range of $11.55 and $12.50 during the previous active session. Cytokinetics, Incorporated (NASDAQ:CYTK) traded with the volume of 1.05 Million with average volume of 456.01 Million. The stock has HIGH volatility on the last trading session.

Currently the Beta for the company remains at 1.8 while ATR (Average True Range) and RSI (Relative Strength Index) are at 0.67 and 31.43 respectively.

Currently the Insider Ownership of the shares of Cytokinetics, Incorporated (NASDAQ:CYTK) is at 0.4% and the shares outstanding are 53.89 Million.

Important Ratio Analysis

Some important ratios to consider here for Cytokinetics, Incorporated (NASDAQ:CYTK) are discussed below:

Price to Earnings P/E ratio stands at 0 while Forward P/E shows the value of 0.

The Price to Sale P/S and Price to Book P/B shows the value of 13.44 and 4.23 respectively. While Price to Cash P/C and Price to Free Cash Flow P/FCF stands at 2.03 and 0 correspondingly.

The Quick Ratio of Cytokinetics, Incorporated (NASDAQ:CYTK) stands at 7.6 while the Current Ratio depicts the value of 7.6.

Return on Assets ROA of Cytokinetics, Incorporated (NASDAQ:CYTK) is at -29.1% whereas, Return on Equity ROE and Return of Investment ROI of Cytokinetics, Incorporated (NASDAQ:CYTK) stand at -62.6% and 15% respectively.

Stock Performance Analysis

The stock performance of Cytokinetics, Incorporated (NASDAQ:CYTK) on the basis of 5 day trade show the dip of -9.38% whereas, the monthly performance of the stock shows decrease of -24.92%.

The quarterly performance of the stock remained in red zone with the value of -7.2% while six month performance of the shares of Cytokinetics, Incorporated (NASDAQ:CYTK) remained bearish with the count of -19.16%.

The yearly and YTD performance of Cytokinetics, Incorporated (NASDAQ:CYTK) remained mix at 3.57% and -4.53% respectively.